DE602005022056D1 - Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind - Google Patents

Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Info

Publication number
DE602005022056D1
DE602005022056D1 DE602005022056T DE602005022056T DE602005022056D1 DE 602005022056 D1 DE602005022056 D1 DE 602005022056D1 DE 602005022056 T DE602005022056 T DE 602005022056T DE 602005022056 T DE602005022056 T DE 602005022056T DE 602005022056 D1 DE602005022056 D1 DE 602005022056D1
Authority
DE
Germany
Prior art keywords
immunosupppressive
modulation
effect
polypeptide sequences
viral proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022056T
Other languages
English (en)
Inventor
Martial Renard
Marianne Mangeney
Thierry Heidmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Sud Paris 11
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Universite Paris Sud Paris 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Universite Paris Sud Paris 11 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602005022056D1 publication Critical patent/DE602005022056D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602005022056T 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind Active DE602005022056D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (1)

Publication Number Publication Date
DE602005022056D1 true DE602005022056D1 (de) 2010-08-12

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022056T Active DE602005022056D1 (de) 2004-03-30 2005-03-30 Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind

Country Status (14)

Country Link
US (2) US8178657B2 (de)
EP (1) EP1732585B1 (de)
JP (1) JP5060284B2 (de)
CN (1) CN1961001B (de)
AT (1) ATE472334T1 (de)
AU (1) AU2005229411B2 (de)
BR (1) BRPI0509497B1 (de)
CA (1) CA2561376C (de)
DE (1) DE602005022056D1 (de)
ES (1) ES2347445T3 (de)
IL (1) IL178205A (de)
MX (1) MXPA06011272A (de)
WO (1) WO2005095442A1 (de)
ZA (1) ZA200608178B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
BRPI1007376B1 (pt) 2009-01-09 2022-03-22 Centre National De La Recherche Scientifique Novos ligantes de ligação a receptores e seu uso na detecção de células de interesse biológico
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20130260394A1 (en) * 2010-09-17 2013-10-03 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
CN103957932B (zh) * 2011-07-20 2017-06-23 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
JP6415324B2 (ja) * 2011-12-07 2018-10-31 ヴィロキシ エス．エー．エス．Ｖｉｒｏｘｉｓ Ｓ．Ａ．Ｓ． レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
US11535654B2 (en) * 2015-06-11 2022-12-27 Keio University Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector
WO2017054831A1 (en) * 2015-10-01 2017-04-06 Stemguard A/S Use of human derived immunosuppressive proteins and peptides as medicaments
EA202090548A1 (ru) * 2017-09-01 2020-06-23 Инпротер Апс Вакцина для применения в профилактике и/или лечении заболевания
US20220088224A1 (en) 2018-09-18 2022-03-24 Vnv Newco Inc. Arc-based capsids and uses thereof
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4277704A1 (de) 2021-01-13 2023-11-22 Viroxis Masern-hiv- oder masern-htlv-impfstoff

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
CA2005311C (en) * 1988-12-13 2006-05-30 Edward A. Hoover Prototype felv isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
JP2004517839A (ja) * 2000-12-11 2004-06-17 トゥフツ・ユニバーシティ Ｅｂｖ感染およびｅｂｖ関連障害の処置および予防
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
CA2561376C (en) 2016-06-21
US8597657B2 (en) 2013-12-03
ES2347445T3 (es) 2010-10-29
EP1732585A1 (de) 2006-12-20
US20120189647A1 (en) 2012-07-26
JP2008506357A (ja) 2008-03-06
IL178205A (en) 2015-05-31
US8178657B2 (en) 2012-05-15
AU2005229411A1 (en) 2005-10-13
EP1732585B1 (de) 2010-06-30
IL178205A0 (en) 2006-12-31
WO2005095442A1 (en) 2005-10-13
WO2005095442A8 (en) 2006-11-02
US20080008683A1 (en) 2008-01-10
JP5060284B2 (ja) 2012-10-31
BRPI0509497A (pt) 2007-09-11
ATE472334T1 (de) 2010-07-15
CN1961001B (zh) 2012-09-05
CA2561376A1 (en) 2005-10-13
CN1961001A (zh) 2007-05-09
ZA200608178B (en) 2008-10-29
MXPA06011272A (es) 2007-04-17
AU2005229411B2 (en) 2010-11-18
BRPI0509497B1 (pt) 2022-07-19

Similar Documents

Publication Publication Date Title
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
MX2018014228A (es) Proteina de union de albumina sérica de dominio unico.
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
EP4019044A3 (de) Stabilisierte fusionsproteine der virusklasse i
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE486128T1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
UA95446C2 (ru) Мутаци в генах oas1
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
WO2006047728A3 (en) Bmp gene and fusion protein
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
WO2007089923A3 (en) Modifications of cst-ii for increased protein expression
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
MX2023000373A (es) Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
DK1594991T3 (da) Fremgangsmåde til fremstilling af DNA-molekyler
WO2008038296A3 (en) Recombinant calcitonin fused to interleukin-2
MXPA05008925A (es) Ciclooxigenasa-3 humana y usos de la misma.
ATE527354T1 (de) Diabetogene epitope